Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04254172
Other study ID # C3391005
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date February 19, 2020
Est. completion date August 19, 2020

Study information

Verified date October 2021
Source Pfizer
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The purpose of this low interventional study is to collect data on everyday movement in boys with Duchenne muscular dystrophy (DMD) using wearable activity sensors. The activity sensors could provide useful information beyond what is currently collected by functional (movement, strength) assessments in clinic. This information can help with the understanding of the impact of DMD, and perhaps with how possible treatments can affect this impact.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date August 19, 2020
Est. primary completion date August 19, 2020
Accepts healthy volunteers No
Gender Male
Age group 4 Years to 12 Years
Eligibility Inclusion Criteria: - Diagnosis of Duchenne muscular dystrophy confirmed by medical history and genetic testing - Body weight between 15 and 50 kg - Receipt of glucocorticoids for 6 months and a stable daily dose for at least 3 months prior to study entry - Ability to rise from floor within seven (7) seconds and ability to walk Exclusion Criteria: - Current exposure to systemic immunosuppressant agents other than glucocorticoids. - Prior exposure to any gene therapy agent, including exon-skipping and missense agents. - Exposure to other investigational drugs within 30 days or 5 half-lives, whichever is longer. - Any injury which may impact functional testing per investigator's judgement. Previous injuries must be fully healed prior to consenting. Prior lower limb fractures must be fully healed and at least 3 months from injury date at screening. - Any planned surgeries which may impact physical activity and performance. - Presence or history of musculoskeletal or neurological disease in addition to DMD. - Any known allergies or skin reactions to stainless steel, versaflex, and silicon that may cause possible discomfort by wearable sensors. - Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, cancer, autoimmune or allergic disease that may interfere with the study conduct as per investigator's judgment, excluding untreated, asymptomatic, seasonal allergies at time of screening. - Investigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or participants who are Pfizer employees, including their family members, directly involved in the conduct of the study.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
Activity Monitor
Wrist and ankle sensors to be worn continuously for 2-week intervals.

Locations

Country Name City State
United States Nationwide Children's Hospital Columbus Ohio

Sponsors (1)

Lead Sponsor Collaborator
Pfizer

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change from baseline and variability of activity measures baseline, 3, 6, 9, and 12 months
Secondary Mean change from baseline in functional assessment scores obtained in the clinic baseline, 3, 6, 9, and 12 months
Secondary Comparison of mean changes from baseline and correlation coefficient between activity monitoring data and functional data obtained in clinic baseline, 3, 6, 9, and 12 months
See also
  Status Clinical Trial Phase
Terminated NCT02814019 - A Phase III Double-blind Study With Idebenone in Patients With Duchenne Muscular Dystrophy (DMD) Taking Glucocorticoid Steroids Phase 3
Completed NCT01478022 - To Compare the Pharmacokinetics Profiles of ISO 20, IBU 200 and IBU Plus ISO Combinations 200 + 20 Phase 1
Completed NCT00654784 - Efficacy and Tolerability of Idebenone in Boys With Cardiac Dysfunction Associated With Duchenne Muscular Dystrophy Phase 2
Recruiting NCT02614820 - The Safety, Efficacy and Tolerability of Remote Ischemic Preconditioning as a Therapy to DMD N/A
Withdrawn NCT02036463 - A Trial of Chronotherapy of Corticosteroids in Duchenne Muscular Dystrophy Phase 2
Completed NCT02255552 - Study of Eteplirsen in DMD Patients Phase 3
Completed NCT01982695 - Cardiomyopathy in DMD: Lisinopril vs. Losartan N/A
Recruiting NCT05516745 - E-monitoring of PULMonary Function in Patients With Duchenne Muscular Dystrophy at Home" N/A
Completed NCT02420379 - Safety Study of Eteplirsen to Treat Early Stage Duchenne Muscular Dystrophy Phase 2
Active, not recruiting NCT05135663 - Extension Study of NS-089/NCNP-02 in DMD Phase 2
Completed NCT01380964 - Research of Biomarkers in Duchenne Muscular Dystrophy Patients N/A
Completed NCT05990608 - Peabody Developmental Motor Scaling In Children With Period Duchenne Muscular Dystrophy
Recruiting NCT04322357 - Twice Weekly Steroids and Exercise as Therapy for DMD Phase 2
Not yet recruiting NCT06392724 - A Study to Evaluate the Safety and Tolerability of GEN6050X in Duchenne Muscular Dystrophy. Early Phase 1
Completed NCT01540409 - Efficacy, Safety, and Tolerability Rollover Study of Eteplirsen in Subjects With Duchenne Muscular Dystrophy Phase 2
Terminated NCT04184882 - A Study to Assess the Safety, Tolerability and Preliminary Efficacy of ASP0367 (MA-0211) in Pediatric Male Participants With Duchenne Muscular Dystrophy (DMD) Phase 1
Recruiting NCT05524883 - Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Phase 1/Phase 2
Completed NCT01761292 - A Study to Assess Safety/Tolerability, pk, Effects on Histology, Clinical Parameters of Givinostat in Children With DMD Phase 1/Phase 2